Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial for the treatment of eosinophilic esophagitis, with the fifth cohort showing significant improvements in patient outcomes and histology scores. Notably, one patient achieved complete histological remission, and no serious adverse events were reported across all cohorts.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Paramount’s (NASDAQ:PARA) Merger with Skydance May Get Delayed
- Ford (NYSE:F) Cuts Hours At German EV Plant
- Did Intel (NASDAQ:INTC) Win the “Server Recession?”
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
